Results 251 to 260 of about 117,385 (313)

Endobody: Genetically Encodable Nanobody‐CPP Chimeras for Degradation of Membrane and Extracellular Proteins

Advanced Science, EarlyView.
We introduced genetically encodable, receptor‐independent nanobody‐CPP chimeras, termed endobodies, as robust and modular membrane protein degraders. Additionally, proteasome‐targeting domain (PTD)‐tethered endobody demonstrates further enhanced degradation potency.
Chengjian Zhou, Huiping He, Simin Xia, Xi Chen   +3 more
wiley   +1 more source

Two target cells for HPV infection at the cervix? [PDF]

Virus Res
Reich O, Regauer S.
europepmc   +1 more source

Toward Precision Cancer Immunotherapy

Advanced Science, EarlyView.
Shuang Tang, Jean J. Zhao, Ada Hang‐Heng Wong   +2 more
wiley   +1 more source

Isolated ovarian metastasis in otherwise cervix-confined adenocarcinoma of the cervix: A rare clinical conundrum. [PDF]

Gynecol Oncol Rep
Lim LM, Speck SL, Zhang Y, Urban R, Liang MI.   +4 more
europepmc   +1 more source

Role of ADC values in assessing clinical response and identifying residual disease post-chemo radiation in uterine cervix cancer.

Indian J Radiol Imaging, 2019
Jajodia A, Mahawar V, Chaturvedi AK, Rao A, Singla R, Mitra S, Goyal S, Kesan S, Pasricha S, Maheshwari U, Tripathi R, Babu Koyyala VP.   +11 more
europepmc   +1 more source

Cancer of the cervix.

Minnesota medicine, 2003
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Vasectomy and Cancer of the Cervix

New England Journal of Medicine, 1979
PIP: Swan and Brown in a recent issue of the New England Journal of Medicine reported a lower rate of sterilization among patients with cervical cancer or their partners than among matched controls. The major part of this difference was attributed to vasectomies, since 4.3% of patients with cervical cancer, as compared with 19.4% of matched controls ...
S H, Swan, W L, Brown
openaire   +4 more sources

Immunotherapy in cervix cancer

Cancer Treatment Reviews, 2020
The treatment approach to cervix cancer has remained unchanged for several decades and new therapeutic strategies are now required to improve outcomes, as the prognosis is still poor. In the last years, a better understanding of HPV tumor-host immune system interactions and the development of new therapeutics targeting immune checkpoints generated ...
Laura Attademo, Valentina Tuninetti, Carmela Pisano, Sabrina Chiara Cecere, Marilena Di Napoli, Rosa Tambaro, Giorgio Valabrega, Lucia Musacchio, Sergio Venanzio Setola, Patrizia Piccirillo, Daniela Califano, Anna Spina, Simona Losito, Stefano Greggi, Sandro Pignata   +14 more
openaire   +2 more sources

Cancer of the Uterine Cervix

New England Journal of Medicine, 1996
Invasive cervical cancer is uncommon in the United States, with an incidence of 15,800 cases and 4800 deaths in 1995.1 This relatively low incidence is largely due to the effectiveness of screening programs that assess cervical cytology by Pap smear. On a global scale, however, cancer of the cervix is a major cause of death, especially in Third World ...
S A, Cannistra, J M, Niloff
openaire   +2 more sources